Holen Sie sich die Stockscreener-App
6.21
3.85%
0.23
Handel nachbörslich:
6.21
Schlusskurs vom Vortag:
$5.98
Offen:
$6.17
24-Stunden-Volumen:
6.70M
Relative Volume:
1.87
Marktkapitalisierung:
$2.01B
Einnahmen:
$493.67M
Nettoeinkommen (Verlust:
$-104.69M
KGV:
-18.26
EPS:
-0.34
Netto-Cashflow:
$-31.51M
1W Leistung:
-4.90%
1M Leistung:
-4.17%
6M Leistung:
-40.80%
1J Leistung:
-32.72%
1-Tages-Spanne:
$6.09
$6.31
1-Wochen-Bereich:
$5.82
$6.585
52-Wochen-Spanne:
$5.82
$12.65
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Firmenname
Amicus Therapeutics Inc
Sektor
Branche
Telefon
(609) 662-2000
Adresse
47 HULFISH STREET, PRINCETON, NJ
Vergleichen Sie FOLD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
6.21 | 2.01B | 493.67M | -104.69M | -31.51M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | Eingeleitet | Jefferies | Buy |
| 2024-05-30 | Eingeleitet | Wells Fargo | Overweight |
| 2024-05-14 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-12-19 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-04-13 | Fortgesetzt | Goldman | Neutral |
| 2022-01-14 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | Hochstufung | Stifel | Hold → Buy |
| 2021-09-30 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-07-19 | Fortgesetzt | BTIG Research | Buy |
| 2021-05-27 | Eingeleitet | Needham | Hold |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-14 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | Eingeleitet | Stifel | Hold |
| 2021-02-12 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-11-11 | Eingeleitet | Berenberg | Hold |
| 2020-06-17 | Eingeleitet | BTIG Research | Buy |
| 2020-02-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2019-11-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-06-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-06-05 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-04-05 | Eingeleitet | Janney | Buy |
| 2019-01-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-10-29 | Eingeleitet | Citigroup | Neutral |
| 2018-08-17 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | Fortgesetzt | Goldman | Neutral |
| 2017-09-13 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-08-10 | Bestätigt | Chardan Capital Markets | Buy |
| 2017-01-24 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | Eingeleitet | BofA/Merrill | Buy |
| 2016-04-14 | Eingeleitet | Robert W. Baird | Neutral |
| 2016-04-12 | Bestätigt | Chardan Capital Markets | Buy |
| 2015-09-16 | Herabstufung | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | Bestätigt | Chardan Capital Markets | Buy |
Alle ansehen
Amicus Therapeutics Inc Aktie (FOLD) Neueste Nachrichten
Bayesian Capital Management LP Purchases 54,100 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
10 Best Low-Priced Biotech Stocks to Buy Now - Insider Monkey
Balyasny Asset Management L.P. Has $8 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Algert Global LLC Buys 165,923 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Schonfeld Strategic Advisors LLC Has $1.94 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Marshall Wace LLP Boosts Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference - GlobeNewswire
Oversold Conditions For Amicus Therapeutics (FOLD) - Nasdaq
Dimerix strikes $601M Amicus deal for kidney disease drug DMX-200 - BioWorld MedTech
Pompe Disease Market Expected to Experience Major Growth - openPR.com
Voya Investment Management LLC Sells 743,492 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Aquatic Capital Management LLC - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by PDT Partners LLC - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Acquired by Tower Research Capital LLC TRC - MarketBeat
Amicus Therapeutics First Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Dark Forest Capital Management LP Purchases Shares of 38,148 Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
UBS Raises Price Target for Amicus Therapeutics (FOLD) to $22, M - GuruFocus
UBS Raises Price Target for Amicus Therapeutics (FOLD) to $22, Maintains Buy Rating | FOLD Stock News - GuruFocus
Amicus Therapeutics (FOLD) Target Price Lowered by Goldman Sachs | FOLD Stock News - GuruFocus
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls - TradingView
UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Dise - GuruFocus
UBS Boosts Amicus (FOLD) Price Target Despite Revised Pompe Disease Outlook | FOLD Stock News - GuruFocus
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2025 Earnings Call Transcript - Insider Monkey
UBS Adjusts Amicus Therapeutics Price Target to $22 From $21, Maintains Buy Rating - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Dimerix and Amicus to commercialise DMX-200 in US - MSN
Amicus Therapeutics Inc Reports Q1 2025 Earnings: EPS of -$0.07 - GuruFocus
Investor Network: Amicus Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
Dimerix and Amicus Therapeutics Announce Exclusive License Agree - GuruFocus
Amicus Therapeutics Turns to Non-GAAP Q1 Earnings, Revenue Rises; Shares Down - marketscreener.com
Earnings call transcript: Amicus Therapeutics reports Q1 2025 loss, stock drops - Investing.com India
Amicus Therapeutics (FOLD) Q1 Earnings and Revenues Lag Estimates - Yahoo Finance
Amicus Therapeutics: Q1 Earnings Snapshot - San Antonio Express-News
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates - The Manila Times
Amicus Therapeutics Q1 2025 slides: 15% revenue growth, new kidney disease program - Investing.com
Amicus (FOLD) Shows Strong Revenue Growth Amid Recent Quarter Ch - GuruFocus
BRIEF-Amicus Therapeutics Q1 Revenue USD 125.2 Million Vs. IBES Estimate USD 135.9 Million - TradingView
Brokerages Set Amicus Therapeutics, Inc. (NASDAQ:FOLD) Target Price at $16.75 - MarketBeat
Amicus Therapeutics Signs Exclusive License Deal for Dimerix Kidney Disease Therapy - marketscreener.com
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States - The Manila Times
Dimerix Licenses Exclusive U.S. Rights for DMX-200 to Amicus Therapeutics for FSGS Treatment - Nasdaq
Amicus Pays $30M Upfront, Up to $560M Milestones for Breakthrough FSGS Drug Rights - Stock Titan
Amicus Therapeutics Q1 2025 Earnings Preview - MSN
Amicus Therapeutics Earnings Preview - Nasdaq
Finanzdaten der Amicus Therapeutics Inc-Aktie (FOLD)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):